Healthcare / Medical DevicesShenzhen
$15.72
+0.15 (+0.96%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $406.3M · quality 87.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.8B
P/E
71.5x
↑EV/EBITDA
28.0x
↑ROE
3.0%
↑Gross Margin
48.7%
↑Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.6%
FCF CAGR
+3.9%
FCF margin
8.7%
FCF / Net income
4.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.66B · net income $92.6M · FCF $406.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.66B | $4.66B | $4.44B | $4.06B | $3.95B |
| Net Income | $92.6M | $92.6M | $326.3M | $284.4M | $446.5M |
| EBITDA | $310.1M | $310.1M | $658.3M | $519.3M | $739.6M |
| EPS | 0.17 | 0.17 | 0.59 | 0.51 | 0.80 |
| Gross Margin | 48.7% | 48.7% | 54.9% | 53.5% | 52.9% |
| Operating Margin | 6.3% | 6.3% | 11.8% | 11.3% | 12.2% |
| Net Margin | 2.0% | 2.0% | 7.3% | 7.0% | 11.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.25 | 0.35 | 0.47 |
| Current Ratio | 1.20 | 1.20 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $406.3M | $406.3M | $444.6M | $388.5M | $362.1M |
| Returns | |||||
| ROE | 3.0% | 3.0% | 9.7% | 9.2% | 14.3% |
| Valuation | |||||
| P/E | 71.45 | 71.45 | 40.95 | 57.69 | 44.82 |
| EV/EBITDA | 28.04 | 28.04 | 20.28 | 32.15 | 27.69 |
| P/B | 2.78 | 2.78 | 3.98 | 5.33 | 6.43 |
| Growth & Yield | |||||
| Revenue Growth | 4.9% | 4.9% | 9.5% | 2.7% | — |
| EPS Growth | -71.4% | -71.4% | 15.3% | -36.2% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
102.3%
EPS terminal req.
$1.39
Spread vs growth
-173.7%
5Y implied EPS CAGR
58.5%
EPS terminal req.
$1.69
Spread vs growth
-129.9%
10Y implied EPS CAGR
32.1%
EPS terminal req.
$2.72
Spread vs growth
-103.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.3%
Start / end P/E
36.4x → 93.3x
EPS bridge
0.59 → 0.17
Residual
-111.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.